TME Pharma N.V. reported significant advancements in its clinical and regulatory efforts for NOX-A12, a treatment for glioblastoma, achieving a median overall survival of 19.9 months in a recent trial. The FDA granted Fast Track designation and cleared an IND application for a Phase 2 study, paving the way for accelerated development. The company also raised €5 million in funding, enhancing its financial position as it prepares for further clinical trials.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.